The Key Asks outline the top priorities the TB community is requesting member states to include in the Political Declaration which is expected to be endorsed by Heads of State during the UN High-Level Meeting on TB in September.

Access to TB drug bedaquiline, a backbone medicine for drug-resistant TB treatment regimens, remains out of reach for too many.

The Standard sets benchmarks to achieve universal access to WHO-recommended rapid diagnostics, increase bacteriologically confirmed TB and drug resistance detection, and reduce the time to diagnosis.

TAG and IMPAACT4TB project partners release several materials to explain how the identification of nitrosamines in rifampicin and rifapentine may affect the safety and supply of TB medicines, and what this may mean for TB programs and patients.

The accountability report of TB-affected communities and civil society: Priorities to close the deadly divide

The Indian Patent Office takes a laudable step that will pave the way for generic manufacturing of a key TB drug.

Global TB community calls on world leaders to increase political and financial commitments to develop and roll out new TB vaccines as a central part of the global TB response.

On World TB Day 2023, ECDC and WHO/Europe issue a sobering warning that, despite having the tools to end TB, the European Region remains a long way from meeting its End TB Strategy targets.

WHO announces the expanded scope of the WHO Director-General’s Flagship Initiative on TB over the period 2023-2027 to support fast-tracking progress towards ending TB and achieving Universal Health Coverage by 2030.

The Fast Track the Cure campaign demands universal access to six-month drug-resistant TB cure by 2024.